October 20, 2014View all
Hepatitis C (hep C) is a viral disease caused by the Hepatitis C virus (HCV) and transmitted by blood, primarily in health care settings. It can progressively damage the liver, and, if left untreated, cause liver cirrhosis, liver cancer, and death. Hep C is the leading cause of liver cancer and liver transplants. In addition, the virus is associated with a variety of conditions beyond liver disease, including diabetes and depression. In July 2013, the World Health Organization (WHO) estimated that over 150 Million people are chronically infected worldwide. The annual number of deaths due to HCV is estimated at 350,000 globally, or nearly 1,000 per day. The HCV pandemic is concentrated in middle-income countries (MICs); while 15% of the 150 million people with chronic HCV live in High income countries (HICs), 73% live in middle-income countries (MICs) and 12% in low-income countries (LICs).
The hepatitis C market is rapidly evolving as new launches prompt a significant paradigm shift in the treatment of the disease. In 2011, a breakthrough in HCV therapy was witnessed with the first two direct acting anti-HCV drugs (Incivek and Victrelis) came to market and were followed by the market approval of two additional anti-HCV drugs (Sovaldi and Olysio) in 2013. These new drugs have significantly improved HCV cure rates. Hepatitis C virus drug market is expected to nearly quadruple of its current figure by 2014. The world market for HCV drugs represents an area of potential opportunities in developed as well as developing countries. Because of the technological advancements and effectiveness, many big market players are focusing on development of innovative drugs for HCV. Major companies are forming coalitions and agreements to develop effective treatment on Hepatitis C virus. The Hepatitis C (HCV) market is entering a new stage due to the emergence of treatment innovations. The HCV market is expected to have the best growth opportunities over the coming decade.
Scope of Report
- This research report provides an extensive analysis of the Hepatitis C Drugs Market and Forecast (2009 - 2019)
- The report covers historical analysis of Hepatitis C Approved Drugs from 2009 - 2013, along with forecast figures for 2014 - 2019
- The report covers forecasted value of Hepatitis C - Pipeline Drugs Sales from 2014 - 2019
- The report provides a detailed analysis of 9 Companies Hepatitis C Pipeline Drugs - Clinical Trials
- The report gives an insight on the Hepatitis C Deals and Acquisitions 2004 - 2014
iGATE RESEARCH report entitled Worldwide - Hepatitis C Drugs Market and Pipeline Drugs Analysis to 2019 provides an in-depth analysis of the drugs, pipeline drugs and the key players that will shape the future of Hepatitis C Drugs Market. This 103 page report enriched with 27 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.
This Report is analyzed from four view points: Approved drugs sales, Pipeline drugs sales, Company Wise Clinical Trial Analysis and Deals and Acquisitions in Hepatitis C Landscape.
Hepatitis C - Approved Drugs sales and Forecast Analysis (To 2019)
8. Intron A
Hepatitis C - Pipeline Drugs Sales and Forecast (To 2019)
1. HCV Franchise (Bristol-Myers Squibb)
2. HCV Franchise (AbbVie)
3. PEG-Interferon Lambda
5. MK-8742 + MK-5172 33
6. Mericitabine or RG7128
7. Sunvepra (Asunaprevir)
8. ABT-450/r + Ombitasvir (ABT-267) + Dasabuvir (ABT-333)
Company Wise - Hepatitis C Pipeline Drugs Clinical Trials
3. Gilead Sciences
6. Tibotec / Janssen
7. Bristol-Myers Squibb (BMS)